查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
PCR 技术的全球市场：按产品、技术、应用、最终用户、地区划分 - 到 2030 年的预测
市场调查报告书
商品编码
1571024

PCR 技术的全球市场：按产品、技术、应用、最终用户、地区划分 - 到 2030 年的预测

PCR Technologies Market by Product (Instruments, Reagents & Consumables, Software), Application (Genotyping, Diagnostic Applications), Technique (Reverse Transcription PCR, qPCR), End-user (Hospital Labs, Diagnostic Labs) - Global Forecasts to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 305 Pages | 订单完成后即时交付

价格

PCR技术市场规模预计将从2024年的146.1亿美元增加至2030年的218.9亿美元，预测期内复合年增长率为7.0%。感染疾病患者数量的增加和 PCR 技术的不断进步正在推动这个市场。其他因素包括不断上升的研发成本以及越来越多地应用生物标记分析来检测疾病。此外，市场成长也受到 PCR 技术和人工智慧的影响。

调查范围
调查年份 2022-2030
基准年 2023年
预测期 2024-2030
考虑单位 金额（100万美元/10美元）
按细分市场 按产品、技术、应用、最终用户、地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东/非洲

聚合酵素链锁反应(PCR) 的变体称为定量 PCR (qPCR)，有时称为即时PCR，可同时扩增和定量特定 DNA 或 RNA 序列。与仅在反应完成后确定遗传物质是否存在的传统 PCR 不同，qPCR 可以即时追踪反应的进展，并提供有关目标核酸量的定量资讯。 qPCR 设备需求不断增长、疾病流行率不断上升以及技术进步推动了市场的发展。此外，qPCR 是一种高度特异性和灵敏的核酸识别和测量方法，因此对于传染病的诊断是必要的。

各种关键因素正在推动微射流产业医院和诊断中心的发展。一个重要因素是对照护现场的需求不断增加。此外，COVID-19 等感染疾病的增加增加了对临床环境中高效诊断的需求。这些设备降低了成本，加快了测试速度，并提高了诊断精度和准确度。诊断实验室必须使用PCR来识别和诊断各种疾病。这些实验室因其准确性、敏感性和速度而广泛使用 PCR 来诊断遗传异常和感染疾病。

本报告检视了全球 PCR 技术市场，并按产品、技术、应用、最终用户、地区和进入市场的公司概况总结了趋势。

目录

第一章 简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章市场概况

  • 介绍
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 主要相关人员和采购标准
  • 专利分析
  • 2024-2025年重大会议和活动
  • 贸易资料分析
  • 价格分析
  • 未满足的需求和主要问题
  • 生态系分析
  • 供应链分析
  • 影响客户业务的趋势/干扰
  • 技术分析
  • 监管状况
  • 投资金筹措场景
  • 赎回场景分析
  • 人工智慧/产生人工智慧对 PCR 技术市场的影响

第六章 PCR 技术市场，依产品分类

  • 介绍
  • 试剂及耗材
  • 装置
  • 软体和服务

第七章 PCR 技术市场，依技术分类

  • 介绍
  • 即时PCR
  • 常规PCR
  • 数位PCR
  • 逆转录聚合酶连锁反应
  • 热启动PCR
  • 多重PCR
  • 其他的

第八章 PCR 技术市场，依应用分类

  • 介绍
  • 诊断
  • 基因分型
  • 核酸检测
  • 基因表现分析
  • 核酸合成
  • 基因序列分析
  • 环境
  • 标准检验/检验
  • 其他的

第 9 章 PCR 技术市场，依最终用户划分

  • 介绍
  • 医院实验室
  • 诊断实验室
  • 学术和政府机构
  • 製药生物技术公司
  • 其他的

第10章PCR技术市场，按地区

  • 介绍
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第十一章竞争格局

  • 介绍
  • 主要参与企业的策略/秘密
  • 2019-2023年收益分析
  • 2023 年市场占有率分析
  • 企业评估矩阵：主要参与企业，2023
  • 企业评估矩阵：Start-Ups/小型企业，2023 年
  • 企业价值评估及财务指标
  • 产品/品牌比较
  • 竞争场景

第十二章 公司简介

  • 主要参与企业
    • THERMO FISHER SCIENTIFIC INC.
    • F. HOFFMANN-LA ROCHE LTD.
    • AGILENT TECHNOLOGIES, INC.
    • BIO-RAD LABORATORIES, INC.
    • QIAGEN
    • DANAHER CORPORATION
    • ABBOTT
    • TAKARA BIO INC.
    • ANALYTIK JENA GMBH+CO. KG
    • MERCK KGAA
    • BIONEER CORPORATION
    • PERKINELMER
    • BECTON, DICKINSON AND COMPANY
    • STANDARD BIOTOOLS
    • HOLOGIC, INC.
    • LONZA
    • ILLUMINA, INC.
    • SANSURE BIOTECH INC.
  • 其他公司
    • PROMEGA CORPORATION
    • LIMING BIO
    • EPPENDORF SE
    • TRANSGEN BIOTECH CO., LTD.
    • DAAN GENE CO., LTD.
    • BIOBASE GROUP
    • NIPPON GENETICS EUROPE
    • BIOMERIEUX
    • DAIICHI SANKYO COMPANY, LIMITED
    • STILLA
    • GENSCRIPT

第十三章附录

Product Code: AST 7880

The PCR technologies market is projected to reach USD 21.89 Billion by 2030 from USD 14.61 in 2024, growing at a CAGR of 7.0% during the forecast period. The market is growing due to numerous factors.Increasing cases of infectious diseases, and regular advancements in PCR technologies drives this market. Rising expenditure in research and development and increase in application of biomarker profiling to detect diseases are other factors. Additionally, the market growth is affected by inclusion of PCR technology with artificial intelligence.

Scope of the Report
Years Considered for the Study2022-2030
Base Year2023
Forecast Period2024-2030
Units ConsideredValue (USD Million/USD Billion)
SegmentsBy Product, Technique, Application, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

"qPCR to account for largest market share in 2023."

A variant of the Polymerase Chain Reaction (PCR) called quantitative PCR (qPCR), sometimes referred to as real-time PCR, enables the simultaneous amplification and quantification of a particular DNA or RNA sequence. qPCR tracks the reaction in real time as it develops and provides quantitative information on the amount of target nucleic acid, in contrast to traditional PCR, which only identifies the presence of genetic material after the reaction is finished. The market is driven by the rising demand for qPCR instruments, the increasing prevalence of illnesses, and technical advances. Moreover, qPCR is a very specific and sensitive method for identifying and measuring nucleic acids, which makes it necessary for the diagnosis of infectious disorders.

"Diagnostic Laboratories to hold largest share in the market."

Various significant factors are propelling the growth of hospitals and diagnostic centers in the microfluidics industry. One important factor is the rising requirement for point-of-care diagnostics, as they provides quick, on-site testing that improves patient outcomes. Moreover, the requirement for efficacious diagnostics in clinical settings has risen due to the increase in infectious diseases like COVID-19. These equipment decrease cost, expedites testing methods, and improve precision and accuracy of diagnosis. Diagnostic labs require PCR identify and diagnose a variety of illnesses. These labs use PCR extensively because of its precision, sensitivity, and speed in diagnosing genetic abnormalities, and infectious diseases.

"North America to register largest share in 2023."

The largest share was hold by North America in 2023. North America comprise US and Canada.

The growth is supported by increase in drug development associated with genomics. Apart from that, government led initiatives and increase in funding and grants supports growth. The region also has strong presence of prominent players who support the growth of this market by carrying out strategic partnerships, collaborations, expansion and acquisitions. Wide application of PCR methods in hospitals and diagnostic labs of this region is also increasing the demand for microfluidics in North America.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-35%, Tier 2-45%, and Tier 3- 20%
  • By Designation: C-level-- 35%, Director-level-25%, and Others-40%
  • By Region: North America-40%, Europe-30%, Asia Pacific-20%, Latin America- 5%, Middle East and Africa- 5%

Prominent players in the PCR technologies market include F. Hoffman-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Germany), Sansure Biotech Inc. (China) Becton, Dickinson and Company (US) and Analytik Jena AG (Germany), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), Standard Biotools (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Illumina, Inc. (US), Bioneer Corporation (South Korea), PerkinElmer Inc. (US), Hologic Inc. (US),.

Research Coverage

The report comprise segmentation that includes end users, products, applications, and geographic regions. It also discusses the key drivers, restraints, opportunities, and challenges affecting the growth of the PCR technologies market. The research offers stakeholders an assessment of market potential and challenges, with a focus on key players and competitive landscapes. Additionally, micromarkets are assessed according to their overall to the microfluidics sector, growth patterns, and potential. The analysis estimates increase in market segment revenues, focusing on five regions.

Key Benefits of Buying the Report:

This research aids new and existing players in the PCR technologies market to assess the sustainability of their investments by offering detailed information. It offers a dataset to assist in making key decisions. The main advantage of this report includes risk evaluation and offering direction for investment decisions. Market segmentation as per the end-users and geographical areas is offered in the study, that provides analysis and insights. It also provides trends, obstacles, opportunities, and drivers, giving stakeholders the information they need to make strategic decisions.

The report provides the insights on the following pointers:

Analysis of the key drivers, restraints, opportunities, and challenges impacting the PCR technologies market growth: advanced technology and rise in prevalence of infectious diseases ; premium price of devices and strict regulations ; rise in number of diagnostic centers/labs.

Product Development/Innovation: Overview of technologies, research & development ventures and launch of innovative product & service for the microfluidics industry.

Market Development: Details related to profitable markets: this research discussees the PCR technologies business in numerous regions.

Market Diversification: Detailed understanding of advanced products, unexplored areas, latest developments, and investment in the market.

Competitive Assessment: Detailed analysis of market share, services and products offered and key strategies adopted by prominent players such as Danaher Corporation (US), Agilent Technologies, Inc. (US), biomerieux (France), Thermo Fisher Scientific Inc. (US) and Abbott laboratories (US).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 SEGMENTS CONSIDERED
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH DESIGN
    • 2.2.1 SECONDARY RESEARCH
      • 2.2.1.1 Key secondary sources
      • 2.2.1.2 Key objectives of secondary research
      • 2.2.1.3 Key data from secondary sources
    • 2.2.2 PRIMARY RESEARCH
      • 2.2.2.1 Key primary sources
      • 2.2.2.2 Key objectives of primary research
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primaries
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Company revenue estimation approach
      • 2.3.1.2 Customer-based market estimation
      • 2.3.1.3 Top-down approach
      • 2.3.1.4 Primary interviews
    • 2.3.2 GROWTH FORECAST
  • 2.4 DATA TRIANGULATION
  • 2.5 MARKET SHARE ASSESSMENT
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 GROWTH ASSUMPTIONS
  • 2.8 RISK ASSESSMENT
  • 2.9 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 PCR TECHNOLOGIES MARKET OVERVIEW
  • 4.2 PCR TECHNOLOGIES MARKET, BY REGION, 2024 VS. 2030 (USD MILLION)
  • 4.3 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY AND END USER, 2023 (USD MILLION)
  • 4.4 PCR TECHNOLOGIES MARKET: GEOGRAPHIC SNAPSHOT

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing outbreaks of infectious diseases/viral persistence
      • 5.2.1.2 Development of miniaturized and portable point-of-care testing devices
      • 5.2.1.3 Integration of PCR technology with automation and data analysis tools
      • 5.2.1.4 High demand for technologically advanced molecular diagnostics
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Premium product pricing
      • 5.2.2.2 Dearth of skilled healthcare professionals
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increased investments in laboratory infrastructure
      • 5.2.3.2 Rising number of applications in rare sequence detection
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Technical limitations
      • 5.2.4.2 Increased pricing pressure on market players
  • 5.3 VALUE CHAIN ANALYSIS
    • 5.3.1 RESEARCH & DEVELOPMENT
    • 5.3.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
    • 5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
  • 5.4 PORTER'S FIVE FORCES ANALYSIS
    • 5.4.1 THREAT OF NEW ENTRANTS
    • 5.4.2 THREAT OF SUBSTITUTES
    • 5.4.3 BARGAINING POWER OF SUPPLIERS
    • 5.4.4 BARGAINING POWER OF BUYERS
    • 5.4.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.5 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.5.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.5.2 KEY BUYING CRITERIA
  • 5.6 PATENT ANALYSIS
    • 5.6.1 LIST OF MAJOR PATENTS
  • 5.7 KEY CONFERENCES AND EVENTS, 2024-2025
  • 5.8 TRADE DATA ANALYSIS
    • 5.8.1 IMPORT DATA FOR HS CODE 3822
    • 5.8.2 EXPORT DATA FOR HS CODE 3822
  • 5.9 PRICING ANALYSIS
    • 5.9.1 PRICE TRENDS OF PCR TECHNOLOGIES, BY REGION
    • 5.9.2 INDICATIVE SELLING PRICE OF PCR TECHNOLOGY PRODUCTS, BY REGION, 2021-2023
    • 5.9.3 AVERAGE SELLING PRICE TREND, BY REGION
      • 5.9.3.1 Average selling price trend of PCR technology equipment, by region
      • 5.9.3.2 Average selling price trend of PCR instruments, by key player
  • 5.10 UNMET NEEDS AND KEY PAIN POINTS
  • 5.11 ECOSYSTEM ANALYSIS
  • 5.12 SUPPLY CHAIN ANALYSIS
    • 5.12.1 MANUFACTURING COMPANIES
    • 5.12.2 SALES & DISTRIBUTION AGENTS
    • 5.12.3 END USERS
  • 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.14 TECHNOLOGY ANALYSIS
    • 5.14.1 KEY TECHNOLOGIES
      • 5.14.1.1 Thermal cyclers
      • 5.14.1.2 Real-time quantitative PCR
      • 5.14.1.3 Portable and point-of-care PCR
    • 5.14.2 COMPLEMENTARY TECHNOLOGIES
      • 5.14.2.1 Next-generation sequencing
      • 5.14.2.2 Microarrays
      • 5.14.2.3 Lab-on-a-chip devices
      • 5.14.2.4 Robotics and automation
    • 5.14.3 ADJACENT TECHNOLOGIES
      • 5.14.3.1 Mass spectrometry
      • 5.14.3.2 Single-cell sequencing
      • 5.14.3.3 Fluorescence in situ hybridization
  • 5.15 REGULATORY LANDSCAPE
    • 5.15.1 REGULATORY ANALYSIS
      • 5.15.1.1 North America
        • 5.15.1.1.1 US
        • 5.15.1.1.2 Canada
      • 5.15.1.2 Europe
      • 5.15.1.3 Asia Pacific
        • 5.15.1.3.1 Japan
        • 5.15.1.3.2 China
        • 5.15.1.3.3 India
    • 5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.16 INVESTMENT AND FUNDING SCENARIO
  • 5.17 REIMBURSEMENT SCENARIO ANALYSIS
  • 5.18 IMPACT OF AI/GEN AI ON PCR TECHNOLOGIES MARKET

6 PCR TECHNOLOGIES MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 REAGENTS AND CONSUMABLES
    • 6.2.1 INCREASING USE OF DPCR-BASED ANALYTICAL PROCEDURES IN GENETIC RESEARCH AND FORENSICS TO DRIVE MARKET
  • 6.3 INSTRUMENTS
    • 6.3.1 RISING AVAILABILITY OF TECHNOLOGICALLY ADVANCED AND INNOVATIVE PCR INSTRUMENTS TO FUEL MARKET GROWTH
  • 6.4 SOFTWARE AND SERVICES
    • 6.4.1 GROWING DEMAND FOR SPECIALIZED PCR ANALYSIS SOFTWARE FOR ONCOLOGY STUDIES AND FORENSICS TO SPUR MARKET GROWTH

7 PCR TECHNOLOGIES MARKET, BY TECHNIQUE

  • 7.1 INTRODUCTION
  • 7.2 REAL-TIME PCR
    • 7.2.1 RISING ADOPTION OF REAL-TIME PCR AMONG RESEARCHERS AND HEALTHCARE PROFESSIONALS TO PROPEL MARKET GROWTH
  • 7.3 CONVENTIONAL PCR
    • 7.3.1 COST-EFFECTIVENESS AND EASE OF USAGE IN ROUTINE CLONING, GENOTYPING, AND MUTATION ANALYSIS TO FUEL MARKET GROWTH
  • 7.4 DIGITAL PCR
    • 7.4.1 FASTER RESULTS WITH LOWER MARGIN ERRORS TO DRIVE ADOPTION
  • 7.5 REVERSE TRANSCRIPTION PCR
    • 7.5.1 HIGHER SENSITIVITY FOR MEASURING CHANGES IN GENE EXPRESSION TO AUGMENT MARKET GROWTH
  • 7.6 HOT-START PCR
    • 7.6.1 BETTER REACTION SPECIFICITY WITH LOWER ERROR RATES TO FAVOR MARKET GROWTH
  • 7.7 MULTIPLEX PCR
    • 7.7.1 COST-EFFECTIVENESS AND HIGH THROUGHPUT TO AID MARKET GROWTH
  • 7.8 OTHER PCR TECHNIQUES

8 PCR TECHNOLOGIES MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 DIAGNOSTIC APPLICATIONS
    • 8.2.1 UNAVAILABILITY OF REIMBURSEMENTS FOR CLINICAL DIAGNOSTIC TESTS TO LIMIT MARKET GROWTH
  • 8.3 GENOTYPING
    • 8.3.1 LARGE TARGET PATIENT POPULATION FOR CANCER DIAGNOSIS TO AUGMENT MARKET GROWTH
  • 8.4 NUCLEIC ACID DETECTION
    • 8.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO BOOST MARKET GROWTH
  • 8.5 GENE EXPRESSION ANALYSIS
    • 8.5.1 INCREASED R&D FUNDING AND GRANTS FOR PCR TO FAVOR MARKET GROWTH
  • 8.6 NUCLEIC ACID SYNTHESIS
    • 8.6.1 INCREASED FOCUS ON PERSONALIZED AND PRECISE MEDICINES TO SUPPORT MARKET GROWTH
  • 8.7 GENETIC SEQUENCING
    • 8.7.1 TECHNOLOGICAL IMPROVEMENTS AND REDUCED COSTS OF SEQUENCING TO FUEL MARKET GROWTH
  • 8.8 ENVIRONMENTAL APPLICATIONS
    • 8.8.1 STRICT GOVERNMENT ENVIRONMENTAL POLICIES TO PROMOTE USE OF PCR
  • 8.9 STANDARD VALIDATION/VERIFICATION
    • 8.9.1 NEED FOR REGIONAL/GLOBAL VALIDATION FOR COMMERCIAL/NON-COMMERCIAL GUIDELINE FRAMING TO DRIVE MARKET
  • 8.10 OTHER APPLICATIONS

9 PCR TECHNOLOGIES MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 HOSPITAL LABORATORIES
    • 9.2.1 RISING PUBLIC AWARENESS OF ROUTINE CHECKUPS TO SUPPORT MARKET GROWTH
  • 9.3 DIAGNOSTIC LABORATORIES
    • 9.3.1 ESTABLISHMENT OF INDEPENDENT SPECIALIZED DIAGNOSTIC LABORATORIES TO PROPEL MARKET GROWTH
  • 9.4 ACADEMIC AND GOVERNMENT ORGANIZATIONS
    • 9.4.1 INCREASED GOVERNMENT SUPPORT FOR GENOME-BASED RESEARCH TO DRIVE MARKET
  • 9.5 PHARMA-BIOTECH COMPANIES
    • 9.5.1 INCREASING R&D INITIATIVES BY PHARMA-BIOTECH COMPANIES TO DRIVE ADOPTION OF PCR TECHNOLOGIES
  • 9.6 OTHER END USERS

10 PCR TECHNOLOGIES MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 10.2.2 US
      • 10.2.2.1 US to dominate North American PCR technologies market during study period
    • 10.2.3 CANADA
      • 10.2.3.1 Supportive government initiatives for genomics research to aid market growth
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 10.3.2 GERMANY
      • 10.3.2.1 Presence of well-established pharmaceutical and R&D industry to augment market growth
    • 10.3.3 FRANCE
      • 10.3.3.1 Increasing investments in life science R&D for infrastructural development to favor market growth
    • 10.3.4 UK
      • 10.3.4.1 Rising acceptance of genome-based diagnosis by clinicians and healthcare professionals to spur market growth
    • 10.3.5 ITALY
      • 10.3.5.1 Supportive government policies and high healthcare expenditure to boost market growth
    • 10.3.6 SPAIN
      • 10.3.6.1 Increasing funding for life science research and pharmaceutical drug development to boost market growth
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 10.4.2 CHINA
      • 10.4.2.1 Improved public access to modern healthcare facilities and advanced genomics research to fuel market growth
    • 10.4.3 JAPAN
      • 10.4.3.1 Well-established healthcare infrastructure and advanced cancer research activities to support market growth
    • 10.4.4 INDIA
      • 10.4.4.1 Presence of large target patient population and high government healthcare expenditure to support market growth
    • 10.4.5 AUSTRALIA
      • 10.4.5.1 High healthcare expenditure to drive adoption of advanced PCR technologies
    • 10.4.6 SOUTH KOREA
      • 10.4.6.1 Improved medical tourism and prevalence of chronic diseases to propel market growth
    • 10.4.7 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 10.5.2 BRAZIL
      • 10.5.2.1 Growing focus on proteomics and genomics research to drive market
    • 10.5.3 MEXICO
      • 10.5.3.1 Favorable trade agreements to support imports and improve accessibility to PCR instruments
    • 10.5.4 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 10.6.2 GCC COUNTRIES
      • 10.6.2.1 Advancements in healthcare infrastructure and increased focus on personalized medicines to fuel market growth
    • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET
  • 11.3 REVENUE ANALYSIS, 2019-2023
  • 11.4 MARKET SHARE ANALYSIS, 2023
    • 11.4.1 GLOBAL PCR INSTRUMENTS MARKET SHARE, BY KEY PLAYER, 2023
    • 11.4.2 GLOBAL PCR REAGENTS AND CONSUMABLES MARKET SHARE, BY KEY PLAYER, 2023
    • 11.4.3 GLOBAL PCR SOFTWARE AND SERVICES MARKET SHARE, BY KEY PLAYER, 2023
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 11.5.5.1 Company footprint
      • 11.5.5.2 Product footprint
      • 11.5.5.3 Application footprint
      • 11.5.5.4 Technique footprint
      • 11.5.5.5 End-user footprint
      • 11.5.5.6 Region footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • 11.6.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2023
  • 11.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 11.8 PRODUCT/BRAND COMPARISON
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES AND APPROVALS
    • 11.9.2 DEALS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 THERMO FISHER SCIENTIFIC INC.
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products/Services/Solutions offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Product launches and approvals
        • 12.1.1.3.2 Deals
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Key strengths
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses and competitive threats
    • 12.1.2 F. HOFFMANN-LA ROCHE LTD.
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products/Services/Solutions offered
      • 12.1.2.3 Recent developments
        • 12.1.2.3.1 Product launches and approvals
        • 12.1.2.3.2 Deals
      • 12.1.2.4 MnM view
        • 12.1.2.4.1 Key strengths
        • 12.1.2.4.2 Strategic choices
        • 12.1.2.4.3 Weaknesses and competitive threats
    • 12.1.3 AGILENT TECHNOLOGIES, INC.
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products/Services/Solutions offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Product launches
        • 12.1.3.3.2 Deals
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Key strengths
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses and competitive threats
    • 12.1.4 BIO-RAD LABORATORIES, INC.
      • 12.1.4.1 Business overview
      • 12.1.4.2 Products/Services/Solutions offered
      • 12.1.4.3 Recent developments
        • 12.1.4.3.1 Product launches
        • 12.1.4.3.2 Deals
      • 12.1.4.4 MnM view
        • 12.1.4.4.1 Key strengths
        • 12.1.4.4.2 Strategic choices
        • 12.1.4.4.3 Weaknesses and competitive threats
    • 12.1.5 QIAGEN
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products/Services/Solutions offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Product launches and approvals
        • 12.1.5.3.2 Deals
      • 12.1.5.4 MnM view
        • 12.1.5.4.1 Key strengths
        • 12.1.5.4.2 Strategic choices
        • 12.1.5.4.3 Weaknesses and competitive threats
    • 12.1.6 DANAHER CORPORATION
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products/Services/Solutions offered
      • 12.1.6.3 Recent developments
        • 12.1.6.3.1 Product approvals
        • 12.1.6.3.2 Deals
    • 12.1.7 ABBOTT
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products/Services/Solutions offered
      • 12.1.7.3 Recent developments
        • 12.1.7.3.1 Product approvals
    • 12.1.8 TAKARA BIO INC.
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products/Services/Solutions offered
      • 12.1.8.3 Recent developments
        • 12.1.8.3.1 Deals
    • 12.1.9 ANALYTIK JENA GMBH+CO. KG
      • 12.1.9.1 Business overview
      • 12.1.9.2 Products/Services/Solutions offered
      • 12.1.9.3 Recent developments
        • 12.1.9.3.1 Product launches
        • 12.1.9.3.2 Deals
    • 12.1.10 MERCK KGAA
      • 12.1.10.1 Business overview
      • 12.1.10.2 Products/Services/Solutions offered
    • 12.1.11 BIONEER CORPORATION
      • 12.1.11.1 Business overview
      • 12.1.11.2 Products/Services/Solutions offered
    • 12.1.12 PERKINELMER
      • 12.1.12.1 Business overview
      • 12.1.12.2 Products/Services/Solutions offered
      • 12.1.12.3 Recent developments
        • 12.1.12.3.1 Other developments
    • 12.1.13 BECTON, DICKINSON AND COMPANY
      • 12.1.13.1 Business overview
      • 12.1.13.2 Products/Services/Solutions offered
      • 12.1.13.3 Recent developments
        • 12.1.13.3.1 Product launches and approvals
        • 12.1.13.3.2 Deals
    • 12.1.14 STANDARD BIOTOOLS
      • 12.1.14.1 Business overview
      • 12.1.14.2 Products/Services/Solutions offered
    • 12.1.15 HOLOGIC, INC.
      • 12.1.15.1 Business overview
      • 12.1.15.2 Products/Services/Solutions offered
      • 12.1.15.3 Recent developments
        • 12.1.15.3.1 Product launches
    • 12.1.16 LONZA
      • 12.1.16.1 Business overview
      • 12.1.16.2 Products/Services/Solutions offered
    • 12.1.17 ILLUMINA, INC.
      • 12.1.17.1 Business overview
      • 12.1.17.2 Products/Services/Solutions offered
    • 12.1.18 SANSURE BIOTECH INC.
      • 12.1.18.1 Business overview
      • 12.1.18.2 Products/Services/Solutions offered
  • 12.2 OTHER PLAYERS
    • 12.2.1 PROMEGA CORPORATION
    • 12.2.2 LIMING BIO
    • 12.2.3 EPPENDORF SE
    • 12.2.4 TRANSGEN BIOTECH CO., LTD.
    • 12.2.5 DAAN GENE CO., LTD.
    • 12.2.6 BIOBASE GROUP
    • 12.2.7 NIPPON GENETICS EUROPE
    • 12.2.8 BIOMERIEUX
    • 12.2.9 DAIICHI SANKYO COMPANY, LIMITED
    • 12.2.10 STILLA
    • 12.2.11 GENSCRIPT

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 PCR TECHNOLOGIES MARKET: STUDY ASSUMPTIONS
  • TABLE 2 PCR TECHNOLOGIES MARKET: RISK ASSESSMENT
  • TABLE 3 NUMBER OF REPORTED CASES OF INFECTIOUS DISEASES, JANUARY 2019-DECEMBER 2022
  • TABLE 4 ADVANTAGES AND DISADVANTAGES OF REAL-TIME POINT-OF-CARE RT-PCR DEVICES
  • TABLE 5 PCR TECHNOLOGIES MARKET: PORTER'S FIVE FORCES
  • TABLE 6 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
  • TABLE 7 PCR TECHNOLOGIES MARKET: LIST OF MAJOR PATENTS, JANUARY 2022-DECEMBER 2024
  • TABLE 8 PCR TECHNOLOGIES MARKET: LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024-DECEMBER 2025
  • TABLE 9 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 10 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2019-2023 (USD THOUSAND)
  • TABLE 11 INDICATIVE SELLING PRICE OF PCR TECHNOLOGY PRODUCTS, BY REGION, 2021-2023 (USD)
  • TABLE 12 AVERAGE SELLING PRICE OF PCR INSTRUMENTS, BY KEY PLAYER, 2023 (USD)
  • TABLE 13 PCR TECHNOLOGIES MARKET: CURRENT UNMET NEEDS
  • TABLE 14 PCR TECHNOLOGIES MARKET: ROLE IN ECOSYSTEM
  • TABLE 15 US: CLASSIFICATION OF PCR TECHNOLOGY-ASSOCIATED DIAGNOSTIC DEVICES
  • TABLE 16 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 17 EUROPE: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 18 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 19 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 24 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 25 REIMBURSEMENT CODES FOR PCR TESTING, 2023
  • TABLE 26 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 27 PCR TECHNOLOGIES MARKET FOR REAGENTS AND CONSUMABLES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 28 PCR TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 29 PCR TECHNOLOGIES MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 30 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 31 REAL-TIME PCR MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 32 REAL-TIME PCR MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 33 REAL-TIME PCR MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 34 REAL-TIME PCR MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 35 CONVENTIONAL PCR MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 36 CONVENTIONAL PCR MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 37 CONVENTIONAL PCR MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 38 CONVENTIONAL PCR MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 39 DIGITAL PCR MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 40 DIGITAL PCR MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 41 DIGITAL PCR MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 42 DIGITAL PCR MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 43 ONE-STEP RT-PCR VS. TWO-STEP RT-PCR
  • TABLE 44 REVERSE TRANSCRIPTION PCR MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 45 REVERSE TRANSCRIPTION PCR MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 46 REVERSE TRANSCRIPTION PCR MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 47 REVERSE TRANSCRIPTION PCR MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 48 BENEFITS AND CONSIDERATIONS OF HOT-START PCR TECHNOLOGY
  • TABLE 49 HOT-START PCR MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 50 HOT-START PCR MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 51 HOT-START PCR MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 52 HOT-START PCR MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 53 MULTIPLEX PCR MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 54 MULTIPLEX PCR MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 55 MULTIPLEX PCR MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 56 MULTIPLEX PCR MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 57 OTHER PCR TECHNIQUES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 58 OTHER PCR TECHNIQUES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 59 OTHER PCR TECHNIQUES MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 60 OTHER PCR TECHNIQUES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 61 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 62 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 63 PCR TECHNOLOGIES MARKET FOR GENOTYPING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 64 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID DETECTION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 65 PCR TECHNOLOGIES MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 66 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID SYNTHESIS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 67 PCR TECHNOLOGIES MARKET FOR GENETIC SEQUENCING, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 68 PCR TECHNOLOGIES MARKET FOR ENVIRONMENTAL APPLICATIONS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 69 PCR TECHNOLOGIES MARKET FOR STANDARD VALIDATION/VERIFICATION, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 70 PCR TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 71 PCR TECHNOLOGIES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 72 PCR TECHNOLOGIES MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 73 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 74 PCR TECHNOLOGIES MARKET FOR ACADEMIC AND GOVERNMENT ORGANIZATIONS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 75 PCR TECHNOLOGIES MARKET FOR PHARMA-BIOTECH COMPANIES, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 76 PCR TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 77 PCR TECHNOLOGIES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 78 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 79 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 80 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 81 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 82 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 83 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 84 US: KEY MACROINDICATORS
  • TABLE 85 US: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 86 US: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 87 CANADA: KEY MACROINDICATORS
  • TABLE 88 CANADA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 89 CANADA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 90 EUROPE: KEY MACROINDICATORS
  • TABLE 91 EUROPE: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 92 EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 93 EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 94 EUROPE: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 95 EUROPE: PCR TECHNOLOGIES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 96 GERMANY: KEY MACROINDICATORS
  • TABLE 97 GERMANY: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 98 GERMANY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 99 FRANCE: KEY MACROINDICATORS
  • TABLE 100 FRANCE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 101 FRANCE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 102 UK: KEY MACROINDICATORS
  • TABLE 103 UK: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 104 UK: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 105 ITALY: KEY MACROINDICATORS
  • TABLE 106 ITALY: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 107 ITALY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 108 SPAIN: KEY MACROINDICATORS
  • TABLE 109 SPAIN: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 110 SPAIN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 111 REST OF EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 112 REST OF EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 114 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 118 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 119 CHINA: KEY MACROINDICATORS
  • TABLE 120 CHINA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 121 CHINA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 122 JAPAN: KEY MACROINDICATORS
  • TABLE 123 JAPAN: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 124 JAPAN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 125 INDIA: KEY MACROINDICATORS
  • TABLE 126 INDIA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 127 INDIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 128 AUSTRALIA: KEY MACROINDICATORS
  • TABLE 129 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 130 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 131 SOUTH KOREA: KEY MACROINDICATORS
  • TABLE 132 SOUTH KOREA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 133 SOUTH KOREA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 134 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 135 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 136 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 137 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 138 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 139 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 140 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 141 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 142 BRAZIL: KEY MACROINDICATORS
  • TABLE 143 BRAZIL: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 144 BRAZIL: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 145 MEXICO: KEY MACROINDICATORS
  • TABLE 146 MEXICO: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 147 MEXICO: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 148 REST OF LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 149 REST OF LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 150 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY REGION, 2022-2030 (USD MILLION)
  • TABLE 151 MIDDLE EAST & AFRICA: KEY MACROINDICATORS
  • TABLE 152 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 153 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 154 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
  • TABLE 155 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 156 GCC COUNTRIES: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 157 GCC COUNTRIES: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 158 REST OF MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 159 REST OF MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2022-2030 (USD MILLION)
  • TABLE 160 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET
  • TABLE 161 PCR TECHNOLOGIES MARKET: DEGREE OF COMPETITION
  • TABLE 162 PCR TECHNOLOGIES MARKET: PRODUCT FOOTPRINT
  • TABLE 163 PCR TECHNOLOGIES MARKET: APPLICATION FOOTPRINT
  • TABLE 164 PCR TECHNOLOGIES MARKET: TECHNIQUE FOOTPRINT
  • TABLE 165 PCR TECHNOLOGIES MARKET: END-USER FOOTPRINT
  • TABLE 166 PCR TECHNOLOGIES MARKET: REGION FOOTPRINT
  • TABLE 167 PCR TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 168 PCR TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 169 PCR TECHNOLOGIES MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 170 PCR TECHNOLOGIES MARKET: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 171 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 172 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 173 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 174 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 175 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 176 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 177 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 178 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 179 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 180 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 181 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024
  • TABLE 182 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 183 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 184 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 185 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024
  • TABLE 186 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 187 QIAGEN: COMPANY OVERVIEW
  • TABLE 188 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 189 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 190 QIAGEN: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 191 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 192 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 193 DANAHER CORPORATION: PRODUCT APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 194 DANAHER CORPORATION: DEALS, JANUARY 2021- AUGUST 2024
  • TABLE 195 ABBOTT: COMPANY OVERVIEW
  • TABLE 196 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 197 ABBOTT: PRODUCT APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 198 TAKARA BIO INC.: COMPANY OVERVIEW
  • TABLE 199 TAKARA BIO INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 200 TAKARA BIO INC.: DEALS, JANUARY 2021- AUGUST 2024
  • TABLE 201 ANALYTIK JENA GMBH+CO. KG: COMPANY OVERVIEW
  • TABLE 202 ANALYTIK JENA GMBH+CO. KG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 203 ANALYTIK JENA GMBH+CO. KG: PRODUCT LAUNCHES, JANUARY 2021- AUGUST 2024
  • TABLE 204 ANALYTIK JENA GMBH+CO. KG: DEALS, JANUARY 2021- AUGUST 2024
  • TABLE 205 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 206 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 207 BIONEER CORPORATION: COMPANY OVERVIEW
  • TABLE 208 BIONEER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 209 PERKINELMER: COMPANY OVERVIEW
  • TABLE 210 PERKINELMER: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 211 PERKINELMER: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
  • TABLE 212 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 213 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 214 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-AUGUST 2024
  • TABLE 215 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 216 STANDARD BIOTOOLS: COMPANY OVERVIEW
  • TABLE 217 STANDARD BIOTOOLS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 218 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 219 HOLOGIC, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 220 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024
  • TABLE 221 LONZA: COMPANY OVERVIEW
  • TABLE 222 LONZA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 223 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 224 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 225 SANSURE BIOTECH INC.: COMPANY OVERVIEW
  • TABLE 226 SANSURE BIOTECH INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 227 PROMEGA CORPORATION: COMPANY OVERVIEW
  • TABLE 228 LIMINGBIO: COMPANY OVERVIEW
  • TABLE 229 EPPENDORF SE: COMPANY OVERVIEW
  • TABLE 230 TRANSGEN BIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 231 DAAN GENE CO., LTD.: COMPANY OVERVIEW
  • TABLE 232 BIOBASE GROUP: COMPANY OVERVIEW
  • TABLE 233 NIPPON GENETICS EUROPE: COMPANY OVERVIEW
  • TABLE 234 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 235 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW
  • TABLE 236 STILLA: COMPANY OVERVIEW
  • TABLE 237 GENSCRIPT: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 PCR TECHNOLOGIES MARKET: SEGMENTS CONSIDERED
  • FIGURE 2 PCR TECHNOLOGIES MARKET: YEARS CONSIDERED
  • FIGURE 3 PCR TECHNOLOGIES MARKET: RESEARCH DATA
  • FIGURE 4 PCR TECHNOLOGIES MARKET: RESEARCH DESIGN
  • FIGURE 5 PCR TECHNOLOGIES MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 6 PCR TECHNOLOGIES MARKET: KEY PRIMARY SOURCES (DEMAND AND SUPPLY SIDES)
  • FIGURE 7 PCR TECHNOLOGIES MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS
  • FIGURE 8 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 9 BREAKDOWN OF PRIMARIES: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 10 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 11 PCR TECHNOLOGIES MARKET SIZE ESTIMATION: COMPANY REVENUE ESTIMATION
  • FIGURE 12 PCR TECHNOLOGIES MARKET: BOTTOM-UP APPROACH
  • FIGURE 13 PCR TECHNOLOGIES MARKET: TOP-DOWN APPROACH
  • FIGURE 14 DATA TRIANGULATION METHODOLOGY
  • FIGURE 15 GROWTH PROJECTIONS ON REVENUE IMPACT OF KEY MACROINDICATORS
  • FIGURE 16 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024 VS. 2030 (USD MILLION)
  • FIGURE 17 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024 VS. 2030 (USD MILLION)
  • FIGURE 18 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION)
  • FIGURE 19 PCR TECHNOLOGIES MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)
  • FIGURE 20 PCR TECHNOLOGIES MARKET: REGIONAL SNAPSHOT
  • FIGURE 21 INCREASING DEMAND FOR ADVANCED PCR TECHNOLOGIES TO DRIVE MARKET
  • FIGURE 22 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING STUDY PERIOD
  • FIGURE 23 US AND DIAGNOSTIC LABORATORIES COMMANDED LARGEST MARKET SHARE IN 2023
  • FIGURE 24 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2030
  • FIGURE 25 PCR TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 26 PCR TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 27 PCR TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • FIGURE 29 KEY BUYING CRITERIA FOR TOP FOUR END USERS
  • FIGURE 30 PATENT ANALYSIS FOR PCR TECHNOLOGIES (JANUARY 2014-AUGUST 2024)
  • FIGURE 31 AVERAGE SELLING PRICE TREND OF PCR TECHNOLOGY EQUIPMENT, BY REGION, 2021-2023 (USD)
  • FIGURE 32 AVERAGE SELLING PRICE OF PCR INSTRUMENTS, BY KEY PLAYER, 2023 (USD)
  • FIGURE 33 PCR TECHNOLOGIES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 34 PCR TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 35 PCR TECHNOLOGIES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 36 INVESTMENT AND FUNDING SCENARIO, 2019-2023
  • FIGURE 37 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023
  • FIGURE 38 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023 (USD MILLION)
  • FIGURE 39 PCR TECHNOLOGIES MARKET: IMPACT OF AI/GEN AI
  • FIGURE 40 NORTH AMERICA: PCR TECHNOLOGIES MARKET SNAPSHOT
  • FIGURE 41 ASIA PACIFIC: PCR TECHNOLOGIES MARKET SNAPSHOT
  • FIGURE 42 REVENUE ANALYSIS OF KEY PLAYERS IN PCR TECHNOLOGIES MARKET (2019-2023)
  • FIGURE 43 PCR INSTRUMENTS MARKET SHARE ANALYSIS (2023)
  • FIGURE 44 PCR REAGENTS AND CONSUMABLES MARKET SHARE ANALYSIS (2023)
  • FIGURE 45 PCR SOFTWARE AND SERVICES MARKET SHARE ANALYSIS (2023)
  • FIGURE 46 PCR TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 47 PCR TECHNOLOGIES MARKET: COMPANY FOOTPRINT
  • FIGURE 48 PCR TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 49 EV/EBITDA OF KEY VENDORS
  • FIGURE 50 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 51 PCR TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 52 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • FIGURE 53 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • FIGURE 54 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • FIGURE 55 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • FIGURE 56 QIAGEN: COMPANY SNAPSHOT
  • FIGURE 57 DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 58 ABBOTT: COMPANY SNAPSHOT
  • FIGURE 59 TAKARA BIO INC.: COMPANY SNAPSHOT
  • FIGURE 60 MERCK KGAA: COMPANY SNAPSHOT
  • FIGURE 61 BIONEER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 62 PERKINELMER: COMPANY SNAPSHOT
  • FIGURE 63 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 64 STANDARD BIOTOOLS: COMPANY SNAPSHOT
  • FIGURE 65 HOLOGIC, INC.: COMPANY SNAPSHOT
  • FIGURE 66 LONZA: COMPANY SNAPSHOT
  • FIGURE 67 ILLUMINA, INC.: COMPANY SNAPSHOT
  • FIGURE 68 SANSURE BIOTECH INC.: COMPANY SNAPSHOT